Prosper AI vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC S23 healthcare AI phone agents automating 50-70% of inbound calls for scheduling, prior auth, and claims; $5M Emergence Capital seed Sep 2025 with 4x revenue growth competing with Nuance and Luma Health for the $200B healthcare admin voice automation market.
About
Prosper AI is a San Francisco-based healthcare AI voice automation company — backed by Y Combinator (S23) with $5 million in seed funding in September 2025 led by Emergence Capital — providing healthcare providers with AI phone agents that automate inbound patient call workflows including patient scheduling, balance reminders, claims status checks, benefits verification, and prior authorization status inquiries — achieving 50-70% inbound call automation rates with 99% IVR navigation accuracy. Founded in 2023 by Josep Mingot and Xavier de Gracia (MIT and Harvard alumni), Prosper AI achieved 4x revenue growth since Q2 2025, addressing the $450 billion US healthcare administrative overhead crisis where an estimated $200 billion in administrative costs come from phone-based patient-provider communication inefficiencies.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.